Free Trial
OTCMKTS:FPMI

FluoroPharma Medical (FPMI) Stock Price, News & Analysis

FluoroPharma Medical logo

About FluoroPharma Medical Stock (OTCMKTS:FPMI)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

Receive FPMI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FluoroPharma Medical and its competitors with MarketBeat's FREE daily newsletter.

FPMI Stock News Headlines

FPMI FluoroPharma Medical, Inc.
A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
FluoroPharma Medical Inc
FluoroPharma Medical Inc (FPMI)
See More Headlines

FPMI Stock Analysis - Frequently Asked Questions

FluoroPharma Medical Inc. (OTCMKTS:FPMI) announced its quarterly earnings results on Friday, August, 14th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Shares of FPMI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that FluoroPharma Medical investors own include Adicet Bio (ACET), Marin Software (MRIN), Aurora Cannabis (ACB), AB Corporate Bond ETF (EYEG), Designer Brands (DBI), Capricorn Energy (CNE) and Comcast (CMCSA).

Company Calendar

Last Earnings
8/14/2015
Today
6/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:FPMI
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (OTCMKTS:FPMI) was last updated on 6/18/2025 by MarketBeat.com Staff
From Our Partners